ebselen has been researched along with manganese in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buckett, PD; Wessling-Resnick, M; Wetli, HA | 1 |
| Andrade, V; Aschner, M; Batoreu, MC; Lucas, RL; Mateus, ML; Milatovic, D; Santos, AP | 1 |
2 other study(ies) available for ebselen and manganese
| Article | Year |
|---|---|
Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake.
Topics: Antioxidants; Azoles; Cation Transport Proteins; Cell Line; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ferric Compounds; Ferrous Compounds; Fluoresceins; Humans; Inhibitory Concentration 50; Ion Transport; Isoindoles; Manganese; Organoselenium Compounds; Proline; Thiocarbamates; Transfection | 2006 |
Protective effects of ebselen (Ebs) and para-aminosalicylic acid (PAS) against manganese (Mn)-induced neurotoxicity.
Topics: Aminosalicylic Acid; Animals; Azoles; Behavior, Animal; Biomarkers; Brain; Disease Models, Animal; Inflammation; Isoindoles; Male; Manganese; Motor Activity; Neuroprotective Agents; Neurotoxicity Syndromes; Organoselenium Compounds; Oxidative Stress; Rats; Rats, Wistar; Tissue Distribution | 2012 |